tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia
PremiumCompany AnnouncementsLarimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia
12d ago
Larimar Therapeutics Reports Promising Clinical Data Update
Premium
Company Announcements
Larimar Therapeutics Reports Promising Clinical Data Update
25d ago
3 Best Stocks to Buy Now, 10/6/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 10/6/2025, According to Top Analysts
1M ago
Larimar Therapeutics price target lowered to $7 from $10 at Baird
PremiumThe FlyLarimar Therapeutics price target lowered to $7 from $10 at Baird
1M ago
Buy Rating for Larimar Therapeutics Driven by Promising Data and Unmet Need in Friedreich’s Ataxia
Premium
Ratings
Buy Rating for Larimar Therapeutics Driven by Promising Data and Unmet Need in Friedreich’s Ataxia
1M ago
EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz
Premium
The Fly
EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz
1M ago
Buy Rating for Larimar Therapeutics Driven by Positive Physician Sentiment and Promising Prospects for Nomlabofusp
PremiumRatingsBuy Rating for Larimar Therapeutics Driven by Positive Physician Sentiment and Promising Prospects for Nomlabofusp
2M ago
3 Best Stocks to Buy Now, 9/1/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 9/1/2025, According to Top Analysts
2M ago
Promising Developments and Strategic Timeline Drive Buy Rating for Larimar Therapeutics
Premium
Ratings
Promising Developments and Strategic Timeline Drive Buy Rating for Larimar Therapeutics
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100